Synthena ^Company

Synthena is a biotechnology company that focuses on developing and selling new drugs to treat severe neuromuscular diseases by modifying RNA. Their proprietary tricyclo-DNA technology platform provides benefits over other oligonucleotide chemistries for RNA intervention strategies. The company's primary preclinical drug development program is centered around Duchenne Muscular Dystrophy, a genetic disorder that affects 1/3,500 boys and can lead to early death.